Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DUVOID vs ISOPTO CARPINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective alpha-1A adrenergic receptor antagonist; relaxes smooth muscle in the bladder neck and prostate, reducing outflow resistance.
Pilocarpine, a direct-acting cholinergic agonist, stimulates muscarinic receptors (M3 subtype) in the ciliary muscle and iris sphincter muscle, causing miosis and contraction of the ciliary muscle. This opens the trabecular meshwork and increases aqueous humor outflow facility, reducing intraocular pressure in glaucoma. Also induces accommodation spasm.
Benign prostatic hyperplasia (BPH) - treatment of symptoms,Off-label: None established
FDA: For the treatment of elevated intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.,Off-label: Emergency reduction of intraocular pressure in acute angle-closure glaucoma, induction of miosis during ocular surgery, diagnosis of Adie's tonic pupil.
100 mg orally three times daily.
1 to 2 drops of a 1% to 4% solution in the affected eye(s) up to 4 times daily, as needed to reduce intraocular pressure.
Terminal elimination half-life is 12–15 hours in patients with normal renal function; prolonged to 24 hours or more in moderate-to-severe renal impairment.
Terminal elimination half-life is approximately 1.4 hours in healthy adults; clinically, this short half-life necessitates frequent dosing for sustained ocular effect.
Extensively metabolized in the liver primarily by CYP2D6 and CYP3A4, with possible minor contributions from other CYPs.
Primarily metabolized by plasma esterases via hydrolysis, with some hepatic metabolism. Half-life ~1-2 hours. Excreted renally as metabolites and unchanged drug.
Renal elimination accounts for approximately 90% of a dose as unchanged drug; biliary/fecal excretion is minor (<10%).
Primarily renal excretion of unchanged drug and metabolites; approximately 80% of a dose is eliminated via urine within 24 hours, with about 20% as unchanged pilocarpine. Biliary/fecal elimination accounts for less than 5%.
Approximately 50–70% bound to plasma proteins, primarily albumin.
Approximately 30% bound to plasma proteins, mainly albumin.
Vd approximately 0.6 L/kg, indicating distribution into total body water.
Approximately 0.5 L/kg, indicating distribution largely into extracellular fluid; clinically, not extensively distributed to tissues.
Oral: 75–85% (may be decreased with food); subcutaneous: nearly 100%.
Ocular (topical): bioavailability is low due to nasolacrimal drainage and systemic absorption; exact % not well defined but systemic exposure is minimal with recommended ophthalmic dosing.
GFR 30-89 m L/min: no adjustment; GFR <30 m L/min: avoid use.
No dosage adjustment required for renal impairment; drug is minimally systemically absorbed and renally eliminated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 50 mg twice daily; Child-Pugh C: avoid use.
No dosage adjustment required for hepatic impairment; drug is minimally systemically absorbed and primarily metabolized locally.
Not recommended for use in pediatric patients.
Not recommended for use in children due to lack of safety and efficacy data; use only if potential benefit outweighs risk.
Initial dose 50 mg twice daily; titrate cautiously due to increased anticholinergic sensitivity.
Use with caution in elderly patients due to increased risk of systemic anticholinergic effects (e.g., bradycardia, bronchospasm); consider lower concentration or frequency.
None.
None
Orthostatic hypotension (especially dose-related; syncope reported),Intraoperative floppy iris syndrome (IFIS) during cataract surgery,Priapism (rare),Dizziness, somnolence, and fatigue may occur,Use caution with hepatic impairment,Avoid use with strong CYP3A4 inhibitors or inducers
Risk of retinal detachment, especially in patients with pre-existing retinal disease or myopia.,May cause ciliary spasm, brow ache, and induced myopia.,Caution in patients with corneal abrasion or contact lens use due to miosis and accommodation effects.,Bronchospasm risk in patients with asthma or COPD.,Bradycardia, hypotension, and increased GI motility (use caution in peptic ulcer disease, urinary tract obstruction, or Parkinson's disease).,Systemic absorption can cause cholinergic toxicity.
Hypersensitivity to DUVOID or any component,Moderate to severe hepatic impairment (Child-Pugh class B or C),Use with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir)
Hypersensitivity to pilocarpine or any component.,Acute iritis, acute anterior uveitis, or acute inflammatory conditions of the anterior chamber.,Narrow-angle glaucoma (unless considered for emergency treatment under specialist care).,Uncontrolled asthma, COPD, or other bronchospastic conditions.,Severe cardiovascular disease (bradycardia, hypotension, recent MI).,Gastrointestinal or urinary tract obstruction.,Concomitant use with other cholinergic agents due to additive toxicity.
Take on an empty stomach; food may decrease absorption. Avoid alcohol as it may increase cholinergic side effects.
No known food interactions.
DUVOID (bethanechol) is classified as FDA Pregnancy Category C. No adequate studies in pregnant women. Animal reproduction studies have not been conducted. Fetal risk cannot be ruled out. Use only if potential benefit justifies potential risk to fetus. No known specific trimester risks.
Insufficient human data. Animal studies: no teratogenicity at ocular doses. Risk cannot be excluded. Avoid in first trimester unless benefit outweighs risk.
It is not known whether bethanechol is excreted in human milk. Caution should be exercised when administered to a nursing woman. M/P ratio is unknown.
Limited data; no M/P ratio available. Pilocarpine may suppress lactation via cholinergic effect. Use caution; monitor infant for cholinergic side effects.
No formal pharmacokinetic studies in pregnancy. Due to increased plasma volume and renal clearance, dose adjustments may be necessary but specific recommendations are lacking. Use lowest effective dose and monitor clinical response.
No established dose adjustments. Monitor IOP closely; pharmacokinetics may be altered due to increased plasma volume and renal clearance. Titrate to effect.
DUVOID (bethanechol) is a cholinergic agonist used for urinary retention. Monitor for cholinergic crisis (excessive salivation, sweating, bradycardia). Administer on an empty stomach to reduce GI upset. Avoid in patients with asthma, hyperthyroidism, peptic ulcer disease, or epilepsy. Atropine is the antidote for overdose.
Isopto Carpine (pilocarpine ophthalmic solution) is a miotic agent used for glaucoma and ocular conditions. It causes miosis and ciliary muscle contraction, reducing intraocular pressure. Onset of miosis is 10–30 minutes, lasting 4–8 hours. Use with caution in patients with retinal detachment, asthma, or bradycardia. Systemic absorption can cause sweating and salivation.
Take this medication on an empty stomach, 1 hour before or 2 hours after meals.,Report any signs of excessive sweating, salivation, or bradycardia to your healthcare provider.,Avoid driving or operating machinery until you know how this drug affects you.,Do not stop taking this medication abruptly; consult your doctor for dose adjustments.,Keep a list of all medications you take and share with your healthcare provider.
Apply pressure to the inner corner of the eye (nasolacrimal occlusion) for 1–2 minutes after instillation to reduce systemic absorption.,Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before use; wait at least 15 minutes before reinserting.,May cause blurred vision, especially at night; avoid driving until vision clears.,Use caution in low-light conditions due to miosis.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DUVOID vs ISOPTO CARPINE, answered by our medical review team.
DUVOID is a Cholinergic Agonist that works by Selective alpha-1A adrenergic receptor antagonist; relaxes smooth muscle in the bladder neck and prostate, reducing outflow resistance.. ISOPTO CARPINE is a Ophthalmic Cholinergic Agonist that works by Pilocarpine, a direct-acting cholinergic agonist, stimulates muscarinic receptors (M3 subtype) in the ciliary muscle and iris sphincter muscle, causing miosis and contraction of the ciliary muscle. This opens the trabecular meshwork and increases aqueous humor outflow facility, reducing intraocular pressure in glaucoma. Also induces accommodation spasm.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DUVOID and ISOPTO CARPINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DUVOID is: 100 mg orally three times daily.. The standard adult dose of ISOPTO CARPINE is: 1 to 2 drops of a 1% to 4% solution in the affected eye(s) up to 4 times daily, as needed to reduce intraocular pressure.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DUVOID and ISOPTO CARPINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DUVOID is classified as Category C. DUVOID (bethanechol) is classified as FDA Pregnancy Category C. No adequate studies in pregnant women. Animal reproduction studies have not been conducted. Fetal risk cannot be rul. ISOPTO CARPINE is classified as Category C. Insufficient human data. Animal studies: no teratogenicity at ocular doses. Risk cannot be excluded. Avoid in first trimester unless benefit outweighs risk.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.